Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine)

Current Opinion in HIV and AIDS

Volumn 4, Issue 6, 2009, Pages 507-512

  Arribas, Jose R ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Darunavir ritonavir; Etravirine; Tipranavir

Indexed keywords

AMPRENAVIR PHOSPHATE; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; ENFUVIRTIDE; ETRAVIRINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SULFONAMIDE; TIPRANAVIR;

CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DECOMPENSATED LIVER CIRRHOSIS; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG CLASSIFICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SALVAGE THERAPY; VIRUS LOAD;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; PYRIDAZINES; PYRIDINES; PYRONES; RITONAVIR; SULFONAMIDES;

EID: 70350524209     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328331b911     Document Type: Review

References (57)

1. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIVinfected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998; 279:930-937.
2. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1- protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351:1881-1883. (Pubitemid 28279721)
3. Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2304-2315.
4. Ruiz L, Martinez-Picado J, Romeu J, et al. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS 2000; 14:397-403.
5. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039-2046.
6. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-260.
7. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850-1861.
8. Lundgren JD, Babiker A, El-Sadr W, et al. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ cell counts and HIV RNA levels during follow-up. J Infect Dis 2008; 197:1145-1155.
9. Willig JH, Abroms S, Westfall AO, et al. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS 2008; 22:1951-1960.
10. Gazzard BG. British HIV Association Guidelines for the treatment of HIV-1- infected adults with antiretroviral therapy 2008. HIV Med 2008; 9:563-608.
11. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
12. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents; 2008. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. [Accessed 15 June 2009]
13. McKinnell JA, Willig JH, Westfall AO, et al. Contemporary antiretroviral therapy: is it time for the generalist to return [abstract #H-1260]. In: Abstracts of the 48th ICAAC and IDSA 46th Annual Meeting; 25-28 October 2008; Washington, DC.
14. Kiselyeva Y, Nedellec R, Ramos A, et al. Evolution of CXCR4-using human immunodeficiency virus type 1 SF162 is associated with two unique envelope mutations. J Virol 2007; 81:3657-3661.
15. Pastore C, Nedellec R, Ramos A, et al. Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J Virol 2006; 80:750-758.
16. Chan SY, Speck RF, Power C, et al. V3 recombinants indicate a central role for CCR5 as a coreceptor in tissue infection by human immunodeficiency virus type 1. J Virol 1999; 73:2350-2358.
17. Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997; 89:263-273.
18. Fletcher CV. Enfuvirtide, a new drug for HIV infection. Lancet 2003; 361:1577-1578.
19. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186-2195.
20. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-2185.
21. Morse C, Maldarelli F. Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: fitness tampering or a case of persistent braking on entering? J Infect Dis 2007; 195:318-321.
22. Matthews T, Salgo M, Greenberg M, et al. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov 2004; 3:215-225.
23. Wild CT, Shugars DC, Greenwell TK, et al. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 1994; 91:9770-9774.
24. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359:1429-1441.
25. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multidrug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006; 368: 466-475.
26. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369:1169-1178.
27. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-354.
28. Bonjoch A, Negredo E, Puig J, et al. Viral failure in HIV-infected patients with long-lasting viral suppression who discontinued enfuvirtide. AIDS 2006; 20:1896-1898.
29. Harris M, Joy R, Larsen G, et al. Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector). AIDS 2006; 20:719-723.
30. Shalit P, True A, Thommes JA. Quality of life and tolerability after administration of enfuvirtide with a thin-walled needle: QUALITE Study. HIV Clin Trials 2007; 8:24-35.
31. Boyd MA, Truman M, Hales G, et al. A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study). Antivir Ther 2008; 13:449-453.
32. De Castro N, Braun J, Charreau I, et al. Switch from enfuvirtide to raltegravir in highly treatment-experienced HIV-1-infected patients: a randomized openlabel noninferiority trial, Easier-ANRS 138 [abstract #572]. In: 16th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montreal, Quebec.
33. Huang W, Toma J, Fransen S, et al. Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein. J Virol 2008; 82:5584-5593.
34. Cormier EG, Dragic T. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J Virol 2002; 76:8953-8957.
35. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008; 16:138-145.
36. Mori J, Mosley M, Lewis M, et al. Characterization of maraviroc resistance in patients failing treatment with CCR5-tropic virus in MOTIVATE 1 and MOTIVATE [abstract #10]. In: Program and Abstracts of the XVI International HIV Drug Resistance Workshop; 12-16 June 2007; St Michael, Barbados.
37. Brumme ZL, Goodrich J, Mayer HB, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005; 192:466-474.
38. Moyle GJ, Wildfire A, Mandalia S, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005; 191:866-872.
39. Briz V, Poveda E, del Mar Gonzalez M, et al. Impact of antiretroviral therapy on viral tropism in HIV-infected patients followed longitudinally for over 5 years. J Antimicrob Chemother 2008; 61:405-410.
40. Demarest J, Bonny T, Vavro C, et al. HIV-1 co-receptor tropism in treatment naive and experienced subjects [abstract #H-1136]. In: Abstracts of the 44th Annual ICAAC Meeting; 30 Oct-2 Nov 2004; Washington, DC.
41. Saag M, Prudence I, Heera J. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive patients infected with R5 HIV 1: week 48 results of the MERIT study [abstract #WESS 104]. In: Abstracts of the Fourth International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention; 23-25 July 2007; Sydney, Australia.
42. Petropoulos CJ, Limoli K, Whitcomb J. Validation studies defining the performance of Monogram's HIV coreceptor tropism assay [abstract #57]. In: Abstracts of the Fifth European HIV Drug Resistance Workshop; 28-30 March 2007; Cascais, Portugal.
43. Heera J, Saag M, Ive P. Virologic correlates associated with treatment failure at week 48 in the Phase 3 study of maraviroc in treatment-naive patients [abstract #40LB]. In: Abstracts of the 15th CROI; 3-6 February 2008; Boston, Massachusetts.
44. Saag M, Heera J, Goodrich J. Reanalysis of the MERIT study with the enhanced Trofile assay (MERIT-ES) [abstract #H-1232a]. In: Abstracts of the 48th ICAAC and IDSA 46th Annual Meeting; 25-28 October 2008; Washington, DC.
45. Edmunds-Ogbuokiri T. An in-depth look at the challenges of prescribing maraviroc. HIV Clin 2008; 20:9-11.
46. McKinnell JA, Lin HY, Nevin CN, et al. Early virologic suppression with threeclass experienced patients: 24-week effectiveness in the darunavir outcomes study. AIDS 2009; 23:1539-1546.
47. Schurmann D, Fatkenheuer G, Reynes J, et al. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS 2007; 21:1293-1299.
48. Strizki JM, Tremblay C, Xu S, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother 2005; 49:4911-4919.
49. Landovitz RJ, Angel JB, Hoffmann C, et al. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J Infect Dis 2008; 198:1113-1122.
50. Zingman B, Suleiman J, DeJesus E, et al. Vicriviroc in combination therapy with an optimized antiretroviral regimen for treatment-experienced subjects: the Victor-E1 Trial. In: 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, Massachusetts.
51. Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007; 196:304-312.
52. Jacobson JM, Saag MS, Thompson MA, et al. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. J Infect Dis 2008; 198:1345-1352.
53. Jacobson JM, Kuritzkes DR, Godofsky E, et al. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX- 355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother 2009; 53:450-457.
54. Kuritzkes DR, Jacobson J, Powderly WG, et al. Antiretroviral activity of the anti- CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 2004; 189:286-291.
55. Reimann KA, Lin W, Bixler S, et al. A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties. AIDS Res Hum Retroviruses 1997; 13:933-943.
56. Boon L, Holland B, Gordon W, et al. Development of anti-CD4MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in nonhuman primates. Toxicology 2002; 172:191-203.
57. Moyle GJ, DeJesus E, Boffito M, et al. CXCR4 antagonism: proof of activity with AMD11070 [abstract #511]. In: Abstracts of the 14th Conference on Retroviruses and Opportunistic Infection; 25-28 February 2007; Los Angeles, California.